Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 132E (TMEM132E) is a widely expressed type I transmembrane protein highly expressed in brain and inner ear tissues, particularly in inner hair cells, where it is implicated in structural and functional regulation of neurons and hair cell development[1][2][3]. Variants in TMEM132E are linked to autosomal recessive nonsyndromic hearing impairment (ARNSHI, DFNB99), and its main molecular function appears to involve connecting the extracellular matrix to the intracellular actin cytoskeleton through extracellular immunoglobulin-like and cohesion domains[1]. The precise molecular mechanism and additional physiological roles are under investigation, but it is not classified as a receptor, channel, enzyme, or classical drug target[2][5][3]. It may play a role in protein trafficking and membrane organization as suggested by some studies[6], and is used primarily as a genetic biomarker in hereditary deafness[1][3]. There are no known approved drugs targeting TMEM132E.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 132E (TMEM132E).